Combination treatment approaches and novel therapies for lymphoma.
D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use; D016207:Cytokines / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use; D011719:Pyrazines / Q000627:therapeutic use; D000069283:Rituximab; D033581:Stem Cell Transplantation
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001897:Boronic Acids; D019496:Cancer Vaccines; D016207:Cytokines; D007155:Immunologic Factors; D009588:Nitrogen Mustard Compounds; D011719:Pyrazines; D000069283:Rituximab; D000069286:Bortezomib; D000069461:Bendamustine Hydrochloride; C437823:galiximab